DREAMADERM has developed both retail and healthcare cosmetic wound-healing product lines formulating the Dermatrix™ technology as either an active or inactive ingredient. For simplicity, two product lines address different type of wounds acute versus chronic. First-aid/retail products address acute wounds, whereas additional, patent-pending products are planned for chronic, slow- or non-healing wounds, as commonly occur in patients with type 2 diabetes.